Cooperative Group Research Endeavors in Small-cell Lung Cancer: Current and Future Directions

Current and Future Directions

Randeep Sangha; Primo N. Lara, Jr.; Alex A. Adjei; Paul Baas; Hak Choy; Laurie E. Gaspar; Glenwood Goss; Nagahiro Saijo; Joan H. Schiller; Everett E. Vokes; David R. Gandara


Clin Lung Cancer. 2009;10(5) 

In This Article

North Central Cancer Treatment Group

The NCCTG is a regional cooperative network based in the Mayo Clinic in Minnesota with a number of centers scattered across the United States, Canada, and Puerto Rico. The NCCTG customarily focuses on phase II clinical trial designs with novel therapeutic agents and also participates in Intergroup protocols such as the ongoing CALGB 30610 trial described earlier. The NCCTG research portfolio recently featured a phase II NCCTG 0621 trial evaluating a novel oral c-SRC inhibitor, saracatinib (AZD0530), administered daily in nonprogressing patients with ES-SCLC who received a maximum of 4 cycles of standard platinum-based chemotherapy (Figure 3). The trial was designed for a primary endpoint of 12-week PFS, and secondary endpoints included RR, OS, and time to treatment failure. Incorporated within the study is an intriguing analysis of the effects of saracatinib treatment on the levels of circulating tumor cells (CTCs) as well as correlative science attempting to determine potential predictive markers of response in CTCs. Complete analysis of the results are eagerly anticipated.

Figure 3.

NCCTG 0621 Treatment Schema: Phase II Trial of Saracatinib (AZD0530) in Extensive-Stage Small-Cell Lung Cancer
a1 cycle = 21 days.
Abbreviations: CR = complete response; ECOG = Eastern Cooperative Oncology Group; ES-SCLC = extensive-stage small-cell lung cancer; NCCTG = North Central Cancer Treatment Group; OS = overall survival; PD = progressive disease; PFS = progression-free survival; p.o. = orally; PS = performance status; RR = response rate; SD = stable disease; TTF = time to treatment failure


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.